[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607941":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":29,"collaborators":25,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":25,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":25,"enrollmentInfo":42,"targetDuration":25,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":25,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":25},{"fullName":5,"class":6},"Benha University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sildosin arm","ACTIVE_COMPARATOR","Oral intake of sildosin",[13],"Drug: Oral intake of sildosin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo arm","PLACEBO_COMPARATOR","Oral intake of placebo",[19],"Other: Oral intake of placebo",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Oral intake of sildosin in male non hormonal contraception",[9],null,{"type":6,"name":17,"description":27,"armGroupLabels":28,"otherNames":25},"Intake of placebo to compare effecacy of other group",[15],{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Mahmoud Mohamed Farag Ali","Lecturer and consultant of urology","100607941","phase-1-sildosin-as-a-male-contraceptive-non-hormonal-100607941",false,"NCT07195097","Sildosin as a Male Contraceptive Non Hormonal","A Prospective Study to Evaluate the Efficacy of Silodosin 8 mg as an on-Demand, Reversible, Nonhormonal Oral Contraceptive for Males:","Inclusion Criteria:\n\n* male sexually active\n\nExclusion Criteria:\n\n* male on oral contraceptives Male with female partner on contraceptives","MALE","20 Years",{"count":43,"type":44},200,"ESTIMATED","INTERVENTIONAL",[47],"PHASE1","In all, 200 healthy, sexually active, fertile male candidates will be assigned 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods will be excluded. Follow up data of total spermatozoa per ejaculate, semen volume and Post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups will be recorded. The various side effects reported in the study groups after 12 weeks from the start of the study will be recorded.",[50],"Contraception Use","NOT_YET_RECRUITING","2025-09-25",{"date":54,"type":55},"2025-09-26","ACTUAL",{"date":57,"type":44},"2025-09",{"date":59,"type":44},"2025-12",{"name":5,"class":6}]